Urinary Peptide Panel to Predict Necessity of Repeated Transurethral Resection of Bladder Tumour

Urinary Peptide Panel to Predict Necessity of Repeated Transurethral Resection of Bladder Tumour - U3P

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039220

Enrollment

500

Registered

2026-03-12

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: prospective collection and analysis of urine specimen of patients who need a re-TURBT (repeat transurethral resection of a bladder tumor) due to a non-muscle-invasive bladder cancer (NMIBC) (

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Initial TURBT for non–muscle-invasive urothelial carcinoma of the urinary bladder (NMIBC) Minimum age of 18 years Informed consent

Exclusion criteria

Exclusion criteria: Macroscopically incomplete initial TURBT (according to the surgeon’s assessment) Concomitant carcinoma in situ / urothelial carcinoma of the upper urinary tract Muscle-invasive urothelial carcinoma of the urinary bladder (MIBC) Recurrent urothelial carcinoma of the urinary bladde

Design outcomes

Primary

Measure	Time frame
Primary endpoints: sensitivity, specificity, PPV, NPV, and AUC of a biomarker panel for the detection of residual tumor at re-TURBT. For this purpose, the developed urinary biomarker panel (proteomic analysis) will be compared with the histopathological report of the re-TURBT. Urine will be collected at the time of re-TURBT and subjected to further proteomic analysis. Measurement time point: day of surgery	—

Measure

Time frame

Primary endpoints: sensitivity, specificity, PPV, NPV, and AUC of a biomarker panel for the detection of residual tumor at re-TURBT. For this purpose, the developed urinary biomarker panel (proteomic analysis) will be compared with the histopathological report of the re-TURBT. Urine will be collected at the time of re-TURBT and subjected to further proteomic analysis. Measurement time point: day of surgery

—

Secondary

Measure	Time frame
see primary endpoints, sex-specific analyses	—

Countries

Germany

Contacts

Public ContactMarie Christine Roesch

Klinik für Urologie des UKSH Campus Lübeck

sekretariat.urologie.luebeck@uksh.de0451 500 43601

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026